New Drug Development for Known and Emerging Viruses
- English
- ePUB (mobile friendly)
- Available on iOS & Android
New Drug Development for Known and Emerging Viruses
About this book
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades
Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic.
New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses.
- Covers the entire field of antiviral drug discovery and development
- Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2
- Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle
- Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues
New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the ;pharmaceutical industry and public health agencies.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover
- Table of Contents
- Title Page
- Copyright
- Preface
- In Memoriam: Farah Elawar
- Introduction
- 1 HIV—Disease Overview, Targets for Therapy and Open Issues
- 2 Curing Hepatitis C with Direct‐Acting Antiviral Therapy
- 3 Antiviral Drugs Against Influenza Virus
- 4 Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics
- 5 Herpes Simplex Viruses
- 6 Antiviral Strategies Against the Human Cytomegalo Virus
- 7 Antiviral Targeting of the Complex Epstein Barr Virus Life Cycle
- 8 Kaposi's Sarcoma‐associated Herpesvirus—Antiviral Treatment
- 10 Hepatitis E Virus—Current Developments in Antiviral Strategies
- 11 Antiviral Therapy of Adenovirus Infections
- 12 ssDNA‐Viruses: Human Parvovirus Infection
- 13 Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections
- 14 Antiviral Strategies Against (Non‐polio) Picornaviruses
- 15 Novel Antiviral Strategies Against Emerging Arbovirus Infections
- 16 Current Therapies for Biosafety Level 4 Pathogens
- 17 A Focus on Severe Acute Respiratory Syndrome (SARS) Coronavirus (SARS‐CoVs) 1 and 2
- Index
- End User License Agreement